Abstract
Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip,
nanotechnology and RNAi, is a new report which provides an in-depth analysis of three technological
innovations that are being heralded to revolutionize the drug discovery process by rapidly
expediting drug discovery research. This report focuses on lab-on-a-chip (LOC) devices,
nanotechnology and RNA interference drug discovery technologies that are increasingly being used to
identify novel drug targets and to successfully reduce R&D timelines. This report also provides:
in-depth analysis of the market forces, current and future technological advances, detailed company
profiles, eight year forecasts of market size for LOC devices, nanotechnology in, drug discovery and
RNA interference technologies and therapeutics. Incorporate the most innovative technologies into
your drug discovery process, significantly reduce R&D timelines and build a unique competitive
edge with the help of this latest report.
Table of Contents
Chapter 1 Introduction 16
- Summary 16
- Overview 17
- A historical overview of the drug discovery process 18
- Drug discovery in the 1950s and 1960s 18
- Drug discovery in the 1980s 19
- Drug discovery today 20
- Emerging drug discovery technologies 22
- Lab-on-a-chip/microfluidic technologies 22
- Nanotechnology 23
- RNA interference 24
- Report objectives 25
Chapter 2 Lab-on-a-chip/microfluidics 27
- Summary 27
- Introduction 28
- LOC technologies 31
- LOC design issues 32
- Microarrays 32
- Spotted microarrays 33
- In situ fabricated arrays 34
- DNA applications 35
- Protein applications 36
- The LabChip 37
- Lab-on-a-CD 41
- Chip-based electrospray system for mass spectroscopy 43
- HPLC-on-a-chip 44
- Microfluidic PCR 45
- Multiplexed capillary electrophoresis 48
- Market drivers and restraints 48
- Market drivers 49
- HTS 49
- Reduction of human error 50
- Reduced exposure to hazardous materials 50
- Reduction in sample requirement and routine tasks 50
- Cost savings 51
- Market restraints 51
- Reduction in demand 51
- Reluctance to replace old systems with new technologies 52
- Market analysis 52
- Competitive structure 54
- Market share 54
- Aclara BioSciences 55
- Advion BioSciences, Inc. 56
- Agilent Technologies 57
- BioMicro Systems 58
- BioTrove Inc. 59
- Caliper Life Sciences 60
- Cepheid 62
- CombiMatrix Corp. 63
- Eksigent Technologies 64
- Epigem Limited 65
- Fluidigm Corp. 66
- Gyros AB 67
- Nanogen 68
- Nanostream Inc. 70
- Protiveris 71
- Sequenom 71
- Zyomyx 72
- Future developments 73
Chapter 3 Nanotechnology 77
- Summary 77
- Introduction 78
- Nanotechnologies 79
- Applications 81
- Drug discovery and drug delivery 81
- Biosensing 82
- Other applications 82
- Public opinion 82
- Funding 83
- Market 84
- Nano-enabled drug discovery tools 84
- Atomic force microscopy 85
- Nano-mass spectroscopy 86
- Dip-pen nanolithography 87
- Nanoarrays 88
- Nanoparticles for drug discovery 90
- Quantum dots and gold nanoparticles 92
- Nanoshells 95
- Nanobarcode particles 97
- Nano-enabled drugs 98
- Abraxane 98
- RenaZorb 98
- Antimicrobial emulsions 99
- Antioxidants and fullerenes 99
- Industry challenges 101
- High demands of drug discovery applications 102
- Long-term stability of nanomaterials 103
- Technical issues in nano-assembly and molecular manufacturing 104
- Barriers to collaborations 104
- Lack of test standardization 104
- Scalability 105
- Pharmaceutical companies reluctant to invest in nanotechnology 105
- Funding for nanotechnology 105
- Market drivers and restraints 106
- Market drivers 108
- Technological drivers 108
- Increased funding 109
- Social and economic factors 110
- Market restraints 111
- Uncertainty 111
- Public awareness 111
- Environmental concerns 112
- Detection of incurable diseases 112
- Large expectations 112
- Market analysis 113
- Competitive structure 114
- Market share 115
- 3DM Inc. 117
- Alnis Biosciences Inc. 118
- American Pharmaceuticals Partners Inc. 119
- BioCrystal Ltd. 120
- BioForce NanoSciences Inc. 120
- CrystalPlex Corp. 122
- C Sixty Inc. 122
- Evident Technologies, Inc. 123
- NanBio Corp. 124
- Nanosphere 125
- PharmaSeq, Inc 126
- Quantum Dot Corp. 128
- Future developments 129
Chapter 4 RNA interference (RNAi) 133
- Summary 133
- Introduction 134
- Gene silencing 137
- Methods for gene silencing 137
- Aptamers 138
- Ribozymes 138
- Peptide nucleic acid (PNA) and PNA-DNA chimeras 140
- Antisense oligonucleotides 140
- RNA interference (RNAi) 142
- RNAi mechanism 142
- RNAi approaches 143
- siRNA 144
- ddRNAi 144
- MicroRNAs (miRNAs) 145
- Short hairpin RNAs (shRNAs) 146
- Delivery methods 146
- Delivery using chemical transfections 147
- Delivery using electroporation 149
- Delivery using expression vectors 149
- Delivery using cell-penetrating peptides 151
- In vivo delivery of siRNAs 151
- Industry challenges 152
- Intellectual property issues 153
- Off-target effects 153
- Delivery of siRNA in vitro and in vivo 154
- Toxicity issues from RNAi 154
- Pricing issues 155
- Efficacy of RNAi 155
- Standardization of technologies 156
- Proof of therapeutic potential 156
- Market drivers and restraints 157
- Market drivers 158
- Demand for accelerated drug discovery 158
- Resolution of intellectual property issues 158
- Robust, efficient and potent technology 158
- Functional genomics and proteomics studies 159
- Vector-based and siRNA price decline 159
- Reliability 159
- Market restraints 160
- Expensive RNAi reagents 160
- Delivery of siRNA 160
- Failure of antisense drugs 160
- Lack of robust clinical data 161
- Selection and design of appropriate siRNA 161
- Toxicity and off-target effects 161
- Market analysis 161
- Revenue forecasts 161
- Trends by geographic region 163
- North America 164
- Europe 164
- Japan 164
- Rest of the World 164
- Competitive structure 165
- Market share analysis 166
- Ambion 168
- Alnylam Pharmaceuticals, Inc. 168
- Benitec Ltd 169
- CytRx Corp. 170
- Cenix BioScience 170
- Devgen 171
- Dharmacon, Inc. 172
- Eurogentec (EGT) 173
- Imgenex Corp. 173
- Immusol Inc. 174
- Invitrogen Corp. 174
- InvivoGen 174
- MWG Biotech 175
- Proligo 175
- Promega 176
- Qiagen. 176
- Sirna Therapeutics 177
- Future developments 178
Chapter 5 Appendix 181
- Research methodology and information sources 181
- Primary research methodology 181
- Secondary research methodology 182
- Market sizing 182
- Forecasting 182
- Index 184
- Abbreviations and acronyms 185
List of Figures
- Figure 1.1: Drug development process during the 1950s and 1960s 19
- Figure 1.2: Drug development process during the 1980s 20
- Figure 1.3: Drug development process today 21
- Figure 2.1: The Gyros Bioaffy lab-on-a-CD 42
- Figure 2.2: Advion BioSciences ESI Chip 44
- Figure 2.3: HPLC-on-a-chip 45
- Figure 2.4: Cepheids GeneXpert cartridges for PCR analysis 47
- Figure 2.5: Market drivers and restraints for LOC/microfluidics devices in drug discovery 49
- Figure 2.6: Microfluidics/LOC revenue forecasts, 2005-2012 53
- Figure 2.7: Microfluidics/lab-on-a-chip market shares, 2004 54
- Figure 3.1: Expression of cells using QDots 94
- Figure 3.2: Binding of Nanospheres nanoparticle probe to a selected genetic or proteomic target
95
- Figure 3.3: Nano-enabled drug discovery industry challenges 102
- Figure 3.4: Market drivers and restraints for nano-enabled drug discovery 107
- Figure 3.5: Nano-enabled drug discovery revenue forecasts, 2004-2012 114
- Figure 3.6: Nanoenabled drug discovery market shares, 2004 116
- Figure 4.7: RNAi pathways 143
- Figure 4.8: Industry challenges faced by RNAi industry participants 152
- Figure 4.9: Market drivers and restraints for RNAi technology 157
- Figure 4.10: RNAi revenue forecasts and growth rates, 2004-2012 162
- Figure 4.11: RNAi revenues by geographic region, 2004 163
- Figure 4.12 RNAi market shares, 2004 166
List of Tables
- Table 2.1: Microfluidics/LOC revenue forecasts, 2005-2012 53
- Table 3.2: Nano-enabled drug discovery revenue forecasts, 2004-2012 113
- Table 4.3: RNAi revenue forecasts, 2004-2012 162
- Table 5.4: Abbreviations and acronyms, A-L 185
- Table 5.5: Abbreviations and acronyms, M-Z 186
医薬品
その他のカテゴリ
FAQ